This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Merck/Organon to acquire Alydia Health and with it...

Merck/Organon to acquire Alydia Health and with it Jade System for prevention of post partum bleeding

Read time: 1 mins
Published:31st Mar 2021
Merck and Alydia Health announced that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death. The transaction is expected to close after Organon has spun off from Merck as a standalone publicly traded company.
Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.